340 results on '"Aaronson N.K."'
Search Results
2. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer
- Author
-
Koole, S.N., Kieffer, J.M., K.Sikorska, Schagen van Leeuwen, J.H., Schreuder, H.W.R., Hermans, R.H., de Hingh, I.H., van der Velden, J., Arts, H.J., van Ham, M.A.P.C., Aalbers, A.G., Verwaal, V.J., Van de Vijver, K.K., Sonke, G.S., van Driel, W.J., and Aaronson, N.K.
- Published
- 2021
- Full Text
- View/download PDF
3. Effects and moderators of coping skills training on symptoms of depression and anxiety in patients with cancer: Aggregate data and individual patient data meta-analyses
- Author
-
Buffart, L.M., Schreurs, M.A.C., Abrahams, H.J.G., Kalter, J., Aaronson, N.K., Jacobsen, P.B., Newton, R.U., Courneya, K.S., Armes, J., Arving, C., Braamse, A.M., Brandberg, Y., Dekker, J., Ferguson, R.J., Gielissen, M.F., Glimelius, B., Goedendorp, M.M., Graves, K.D., Heiney, S.P., Horne, R., Hunter, M.S., Johansson, B., Northouse, L.L., Oldenburg, H.S., Prins, J.B., Savard, J., van Beurden, M., van den Berg, S.W., Brug, J., Knoop, H., and Verdonck-de Leeuw, I.M.
- Published
- 2020
- Full Text
- View/download PDF
4. Effects and moderators of exercise on sleep in adults with cancer: Individual patient data and aggregated meta-analyses
- Author
-
Bernard, P., Savard, J., Steindorf, K., Sweegers, M.G., Courneya, K.S., Newton, R.U., Aaronson, N.K., Jacobsen, P.B., May, A.M., Galvao, D.A., Chinapaw, M.J., Stuiver, M.M., Griffith, K.A., Mesters, I., Knoop, H., Goedendorp, M.M., Bohus, M., Thorsen, L., Schmidt, M.E., Ulrich, C.M., Sonke, G.S., van Harten, W., Winters-Stone, K.M., Velthuis, M.J., Taaffe, D.R., van Mechelen, W., Kersten, M.J., Nollet, F., Wenzel, J., Wiskemann, J., Verdonck-de Leeuw, I.M., Brug, J., and Buffart, L.M.
- Published
- 2019
- Full Text
- View/download PDF
5. A Bayesian adaptive decision-theoretic approach can reduce the sample sizes for multi-arm exercise oncology trials
- Author
-
Buffart, L.M., primary, Bassi, A., additional, Stuiver, M.M., additional, Aaronson, N.K., additional, Sonke, G.S., additional, Berkhof, J., additional, and van de Ven, P.M., additional
- Published
- 2023
- Full Text
- View/download PDF
6. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
- Author
-
Terra, L., Beekman, M.J, Engelhardt, E.G., Heemskerk-Gerritsen, B.A., Beurden, M. van, Roeters van Lennep, J.E., Doorn, H.C. van, Hullu, J.A. de, Dorst, E.B. van, Mom, C.H., Slangen, B.F.M., Gaarenstroom, K.N., Kolk, L.E. van der, Collée, J.M., Wevers, M.R., Ausems, M.G., Engelen, K. van, Beek, I. van de, Berger, L.P.V., Asperen, C.J. van, Gomez Garcia, E.B., Maas, A.H.E.M., Hooning, M.J., Aaronson, N.K., Mourits, M.J., Leeuwen, F.E. van, Terra, L., Beekman, M.J, Engelhardt, E.G., Heemskerk-Gerritsen, B.A., Beurden, M. van, Roeters van Lennep, J.E., Doorn, H.C. van, Hullu, J.A. de, Dorst, E.B. van, Mom, C.H., Slangen, B.F.M., Gaarenstroom, K.N., Kolk, L.E. van der, Collée, J.M., Wevers, M.R., Ausems, M.G., Engelen, K. van, Beek, I. van de, Berger, L.P.V., Asperen, C.J. van, Gomez Garcia, E.B., Maas, A.H.E.M., Hooning, M.J., Aaronson, N.K., Mourits, M.J., and Leeuwen, F.E. van
- Abstract
01 april 2023, Item does not contain fulltext, BACKGROUND: Women with a BRCA1/2 pathogenic variant are advised to undergo premenopausal risk-reducing salpingo-oophorectomy after completion of childbearing, to reduce their risk of ovarian cancer. Several studies reported less sexual pleasure 1 to 3 years after a premenopausal oophorectomy. However, the long-term effects of premenopausal oophorectomy on sexual functioning are unknown. OBJECTIVE: This study aimed to study long-term sexual functioning in women at increased familial risk of breast or ovarian cancer who underwent a risk-reducing salpingo-oophorectomy either before the age of 46 years (premenopausal group) or after the age of 54 years (postmenopausal group). Subgroup analyses were performed in the premenopausal group, comparing early (before the age of 41 years) and later (at ages 41-45 years) premenopausal risk-reducing salpingo-oophorectomy. STUDY DESIGN: Between 2018 and 2021, 817 women with a high familial risk of breast or ovarian cancer from an ongoing cohort study were invited to participate in our study. Because of a large difference in age in the study between the premenopausal and postmenopausal salpingo-oophorectomy groups, we restricted the comparison of sexual functioning between the groups to 368 women who were 60 to 70 years old at completion of the questionnaire (226 in the premenopausal group and 142 in the postmenopausal group). In 496 women with a premenopausal risk-reducing salpingo-oophorectomy, we compared the sexual functioning between women in the early premenopausal group (n=151) and women in the later premenopausal group (n=345). Differences between groups were analyzed using multiple regression analyses, adjusting for current age, breast cancer history, use of hormone replacement therapy, body mass index, chronic medication use (yes or no), and body image. RESULTS: Mean times since risk-reducing salpingo-oophorectomy were 20.6 years in the premenopausal group and 10.6 years in the postmenopausal group (P<.001). The mean age a
- Published
- 2023
7. A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials
- Author
-
Buffart, L.M., Bassi, Andrea, Stuiver, M.M., Aaronson, N.K., Sonke, G.S., Berkhof, Johannes, Ven, Peter M. van de, Buffart, L.M., Bassi, Andrea, Stuiver, M.M., Aaronson, N.K., Sonke, G.S., Berkhof, Johannes, and Ven, Peter M. van de
- Abstract
Item does not contain fulltext
- Published
- 2023
8. Translating Evidence from Dutch Exercise Oncology Trials in Patients with Breast Cancer into Clinical Practice Using the RE-AIM Framework
- Author
-
Tusscher, M. ten, Stuiver, M.M., Kampshoff, Caroline S., Huijsmans, Rosalie J., Aaronson, N.K., Velthuis, M.J., May, Anne M., Buffart, L.M., Tusscher, M. ten, Stuiver, M.M., Kampshoff, Caroline S., Huijsmans, Rosalie J., Aaronson, N.K., Velthuis, M.J., May, Anne M., and Buffart, L.M.
- Abstract
Item does not contain fulltext
- Published
- 2023
9. Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial
- Author
-
Billingy, N.E., Tromp, V.N.M.F., Aaronson, N.K., Hoek, R.J.A., Bogaard, H.J., Onwuteaka-Philipsen, B.D., van de Poll-Franse, L.V., Hugtenburg, Jacqueline g, Belderbos, José, Becker-Commissaris, Annemarie, Van den hurk, Corina j g, Walraven, Iris, Van walree, N c, De jaeger, K, Samii, S, Lam-Wong, W y, Koppe, F, Stigt, J a, Herder, G j m, Welling, A, Schuurbiers-Siebers, O c j, Smit, J m, Staal-Van den brekel, A j, De jong, W k, Billingy, N.E., Tromp, V.N.M.F., Aaronson, N.K., Hoek, R.J.A., Bogaard, H.J., Onwuteaka-Philipsen, B.D., van de Poll-Franse, L.V., Hugtenburg, Jacqueline g, Belderbos, José, Becker-Commissaris, Annemarie, Van den hurk, Corina j g, Walraven, Iris, Van walree, N c, De jaeger, K, Samii, S, Lam-Wong, W y, Koppe, F, Stigt, J a, Herder, G j m, Welling, A, Schuurbiers-Siebers, O c j, Smit, J m, Staal-Van den brekel, A j, and De jong, W k
- Abstract
Background Previous studies using patient-reported outcomes measures (PROMs) to monitor symptoms during and after (lung) cancer treatment used alerts that were sent to the health-care provider, although an approach in which patients receive alerts could be more clinically feasible. The primary aim of this study was to compare the effect of weekly PROM symptom monitoring via a reactive approach (patient receives alert) or active approach (health-care provider receives alert) with care as usual on health-related quality of life (HRQOL) at 15 weeks after start of treatment in lung cancer patients. Methods The SYMPRO–Lung trial is a multicenter randomized controlled trial using a stepped wedge design. Stage I-IV lung cancer patients in the reactive and active groups reported PROM symptoms weekly, which were linked to a common alerting algorithm. HRQOL was measured by the EORTC QLQ-C30 at baseline and after 15 weeks. Linear regression analyses and effect size estimates were used to assess mean QOL–C30 change scores between groups, accounting for confounding. Results A total of 515 patients were included (160 active group, 89 reactive group, 266 control group). No differences in HRQOL were observed between the reactive and active group (summary score: unstandardized beta [B] = 0.51, 95% confidence interval [CI] = -3.22 to 4.24, Cohen d effect size [ES] = 0.06; physical functioning: B = 0.25, 95% CI = -5.15 to 4.64, ES = 0.02). The combined intervention groups had statistically and clinically significantly better mean change scores on the summary score (B = 4.85, 95% CI = 1.96 to 7.73, ES = 0.57) and physical functioning (B = 7.00, 95% CI = 2.90 to 11.09, ES = 0.71) compared with the control group. Conclusions Weekly PRO symptom monitoring statistically and clinically significantly improves HRQOL in lung cancer patients. The logistically less intensive, reactive approach may be a better fit for implementation.
- Published
- 2023
10. Emotionally focused couple therapy in cancer survivor couples with marital and sexual problems: A replicated single case experimental design
- Author
-
van Diest, S.L., den Oudsten, B.L., Aaronson, N.K., Beaulen, A., Verboon, P., Aarnoudse, B., van Lankveld, J.J.D.M., van Diest, S.L., den Oudsten, B.L., Aaronson, N.K., Beaulen, A., Verboon, P., Aarnoudse, B., and van Lankveld, J.J.D.M.
- Abstract
Objective The current research examined the effect of Emotionally Focused Couples Therapy (EFCT) on perceived intimacy, affect, and dyadic connection in cancer survivor couples with relationship challenges. Method In this longitudinal replicated single-case study, positive and negative affect, intimacy, partner responsiveness, and expression of attachment-based emotional needs were reported every 3 days before and during treatment. Thirteen couples, with one partner having survived colorectal cancer or breast cancer, participated for the full duration of the study. Statistical analysis of the data was performed using randomization tests, piecewise regression, and multilevel analyses. Results Adherence to the therapeutic protocol was tested and found adequate. Compared with baseline, significant positive effects on affect variables were found during the therapeutic process. Positive affect increased and negative affect decreased. Partner responsiveness, perceived intimacy, and the expression of attachment-based emotional needs improved, but only in the later phase of treatment. Results at the group level were statistically significant, whereas effects at the individual level were not. Discussion This study found positive group-level effects of EFCT on affect and dyadic outcome measures in cancer survivors. The positive results warrant further research, including randomized clinical trials, to replicate these effects of EFCT in cancer survivor couples experiencing marital and sexual problems.
- Published
- 2023
11. Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT‐C33) and specific complementary outpatient module (EORTC OUT‐PATSAT7)
- Author
-
Brédart, A., Anota, A., Young, T., Tomaszewski, K.A., Arraras, J.I., Moura De Albuquerque Melo, H., Schmidt, H., Friend, E., Bergenmar, M., Costantini, A., Vassiliou, V., Hureaux, J., Marchal, F., Tomaszewska, I.M., Chie, W.‐C., Ramage, J., Beaudeau, A., Conroy, T., Bleiker, E., Kulis, D., Bonnetain, F., and Aaronson, N.K.
- Published
- 2018
- Full Text
- View/download PDF
12. Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire (Jan, 10.1007/s11764-021-01160-1, 2022)
- Author
-
Leeuwen, M. van, Kieffer, J.M., Young, T.E., Aaronson, N.K., Poll-franse, L.V. van de, and EORTC QLG
- Published
- 2022
13. A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study.
- Author
-
Bancroft E.K., Page E.C., Brook M.N., Thomas S., Taylor N., Pope J., McHugh J., Jones A.-B., Karlsson Q., Merson S., Ong K.R., Hoffman J., Huber C., Maehle L., Grindedal E.M., Stormorken A., Evans D.G., Rothwell J., Lalloo F., Brady A.F., Bartlett M., Snape K., Hanson H., James P., McKinley J., Mascarenhas L., Syngal S., Ukaegbu C., Side L., Thomas T., Barwell J., Teixeira M.R., Izatt L., Suri M., Macrae F.A., Poplawski N., Chen-Shtoyerman R., Ahmed M., Musgrave H., Nicolai N., Greenhalgh L., Brewer C., Pachter N., Spigelman A.D., Azzabi A., Helfand B.T., Halliday D., Buys S., Ramon Y Cajal T., Donaldson A., Cooney K.A., Harris M., McGrath J., Davidson R., Taylor A., Cooke P., Myhill K., Hogben M., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Dias A., Dudderidge T., Eccles D.M., Green K., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lilja H., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A.V., Moynihan C., Ni Raghallaigh H., Rennert G., Collier R., Offman J., Kote-Jarai Z., Eeles R.A., Bancroft E.K., Page E.C., Brook M.N., Thomas S., Taylor N., Pope J., McHugh J., Jones A.-B., Karlsson Q., Merson S., Ong K.R., Hoffman J., Huber C., Maehle L., Grindedal E.M., Stormorken A., Evans D.G., Rothwell J., Lalloo F., Brady A.F., Bartlett M., Snape K., Hanson H., James P., McKinley J., Mascarenhas L., Syngal S., Ukaegbu C., Side L., Thomas T., Barwell J., Teixeira M.R., Izatt L., Suri M., Macrae F.A., Poplawski N., Chen-Shtoyerman R., Ahmed M., Musgrave H., Nicolai N., Greenhalgh L., Brewer C., Pachter N., Spigelman A.D., Azzabi A., Helfand B.T., Halliday D., Buys S., Ramon Y Cajal T., Donaldson A., Cooney K.A., Harris M., McGrath J., Davidson R., Taylor A., Cooke P., Myhill K., Hogben M., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Dias A., Dudderidge T., Eccles D.M., Green K., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lilja H., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A.V., Moynihan C., Ni Raghallaigh H., Rennert G., Collier R., Offman J., Kote-Jarai Z., and Eeles R.A.
- Abstract
BACKGROUND: Lynch syndrome is a rare familial cancer syndrome caused by pathogenic variants in the mismatch repair genes MLH1, MSH2, MSH6, or PMS2, that cause predisposition to various cancers, predominantly colorectal and endometrial cancer. Data are emerging that pathogenic variants in mismatch repair genes increase the risk of early-onset aggressive prostate cancer. The IMPACT study is prospectively assessing prostate-specific antigen (PSA) screening in men with germline mismatch repair pathogenic variants. Here, we report the usefulness of PSA screening, prostate cancer incidence, and tumour characteristics after the first screening round in men with and without these germline pathogenic variants. METHOD(S): The IMPACT study is an international, prospective study. Men aged 40-69 years without a previous prostate cancer diagnosis and with a known germline pathogenic variant in the MLH1, MSH2, or MSH6 gene, and age-matched male controls who tested negative for a familial pathogenic variant in these genes were recruited from 34 genetic and urology clinics in eight countries, and underwent a baseline PSA screening. Men who had a PSA level higher than 3.0 ng/mL were offered a transrectal, ultrasound-guided, prostate biopsy and a histopathological analysis was done. All participants are undergoing a minimum of 5 years' annual screening. The primary endpoint was to determine the incidence, stage, and pathology of screening-detected prostate cancer in carriers of pathogenic variants compared with non-carrier controls. We used Fisher's exact test to compare the number of cases, cancer incidence, and positive predictive values of the PSA cutoff and biopsy between carriers and non-carriers and the differences between disease types (ie, cancer vs no cancer, clinically significant cancer vs no cancer). We assessed screening outcomes and tumour characteristics by pathogenic variant status. Here we present results from the first round of PSA screening in the IMPACT study. This
- Published
- 2022
14. Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial
- Author
-
Amelsfoort, Romy M. van, Walraven, I., Kieffer, Jacobien M., Jansen, E.P.M., Cats, A., Grieken, N.C.T. van, Aaronson, N.K., Verheij, M., Amelsfoort, Romy M. van, Walraven, I., Kieffer, Jacobien M., Jansen, E.P.M., Cats, A., Grieken, N.C.T. van, Aaronson, N.K., and Verheij, M.
- Abstract
Item does not contain fulltext
- Published
- 2022
15. Construct Validity of the Steep Ramp Test for Assessing Cardiorespiratory Fitness in Patients With Breast Cancer and the Effect of Chemotherapy-Related Symptom Burden
- Author
-
Wiel, Hester J. Van de, Groen, Wim G., Kampshoff, Caroline S., Buffart, L.M., Mechelen, W. van, Schep, G., Aaronson, N.K., Stuiver, M.M., Wiel, Hester J. Van de, Groen, Wim G., Kampshoff, Caroline S., Buffart, L.M., Mechelen, W. van, Schep, G., Aaronson, N.K., and Stuiver, M.M.
- Abstract
Item does not contain fulltext
- Published
- 2022
16. Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
- Author
-
Ripping, T.M., Westhoff, E., Aaronson, N.K., Hemelrijck, M. Van, Rammant, E., Witjes, J.A., Kiemeney, L.A.L.M., Aben, K.K.H., Vrieling, A., Ripping, T.M., Westhoff, E., Aaronson, N.K., Hemelrijck, M. Van, Rammant, E., Witjes, J.A., Kiemeney, L.A.L.M., Aben, K.K.H., and Vrieling, A.
- Abstract
Contains fulltext : 237711.pdf (Publisher’s version ) (Open Access), BACKGROUND: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psychometric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate and high risk NMIBC. METHODS: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural validity, reliability (i.e. internal consistency and test-retest reliability), construct validity (i.e. divergent validity and known-groups validity), responsiveness and interpretability. RESULTS: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach's α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales 'malaise' and 'bloating and flatulence'. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the questionnaire was good, but the interpretability, i.e. minimal important change, could
- Published
- 2021
17. Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study)
- Author
-
Terra, L., Hooning, M.J., Heemskerk-Gerritsen, B.A., Beurden, M. van, Lennep, J.E.Roeters van, Doorn, H.C. van, de Hullu, J.A., Mom, C., Dorst, E.B.L. van, Mourits, M.J.E., Slangen, B.F.M., Gaarenstroom, K.N., Zillikens, M.C., Leiner, T., Kolk, L. van der, Collee, M., Wevers, M.R., Ausems, M., Engelen, K. van, Berger, L.P.V., Asperen, C.J. van, Gomez-Garcia, E.B., Beek, I. van de, Rookus, Matti A., Hauptmann, M., Bleiker, E.M.A., Schagen, S.B., Aaronson, N.K., Maas, A.H.E.M., Leeuwen, F.E. van, Terra, L., Hooning, M.J., Heemskerk-Gerritsen, B.A., Beurden, M. van, Lennep, J.E.Roeters van, Doorn, H.C. van, de Hullu, J.A., Mom, C., Dorst, E.B.L. van, Mourits, M.J.E., Slangen, B.F.M., Gaarenstroom, K.N., Zillikens, M.C., Leiner, T., Kolk, L. van der, Collee, M., Wevers, M.R., Ausems, M., Engelen, K. van, Berger, L.P.V., Asperen, C.J. van, Gomez-Garcia, E.B., Beek, I. van de, Rookus, Matti A., Hauptmann, M., Bleiker, E.M.A., Schagen, S.B., Aaronson, N.K., Maas, A.H.E.M., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 232463.pdf (Publisher’s version ) (Open Access), BACKGROUND: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal RRSO, such as increased risk of cardiovascular disease, osteoporosis, cognitive dysfunction, and reduced health-related quality of life (HRQoL), is limited. OBJECTIVE: The aim of this study is to assess the long-term health effects of premenopausal RRSO on cardiovascular disease, bone health, cognitive functioning, urological complaints, sexual functioning, and HRQoL in women with high familial risk of breast or ovarian cancer. METHODS: We will conduct a multicenter cross-sectional study with prospective follow-up, nested in a nationwide cohort of women at high familial risk of breast or ovarian cancer. A total of 500 women who have undergone RRSO before 45 years of age, with a follow-up period of at least 10 years, will be compared with 250 women (frequency matched on current age) who have not undergone RRSO or who have undergone RRSO at over 55 years of age. Participants will complete an online questionnaire on lifestyle, medical history, cardiovascular risk factors, osteoporosis, cognitive function, urological complaints, and HRQoL. A full cardiovascular assessment and assessment of bone mineral density will be performed. Blood samples will be obtained for marker analysis. Cognitive functioning will be assessed objectively with an online neuropsychological test battery. RESULTS: This study was approved by the institutional review board in July 2018. In February 2019, we included our first participant. As of November 2020, we had enrolled 364 participants in our study. CONCLUSIONS: Knowledge from this study will contribute to counseling women with a high familial risk of breast/ovarian cancer about the long-term health effects of premenopausal RRSO. The results can also be used to o
- Published
- 2021
18. SYMptom monitoring with Patient-Reported Outcomes using a web application among patients with Lung cancer in the Netherlands (SYMPRO-Lung): study protocol for a stepped-wedge randomised controlled trial
- Author
-
Billingy, Nicole E., Tromp, Vashti N.M.F., Veldhuijzen, E., Belderbos, J., Aaronson, N.K., Feldman, E., Becker-Commissaris, Annemarie, Walraven, I., Billingy, Nicole E., Tromp, Vashti N.M.F., Veldhuijzen, E., Belderbos, J., Aaronson, N.K., Feldman, E., Becker-Commissaris, Annemarie, and Walraven, I.
- Abstract
Contains fulltext : 238462.pdf (Publisher’s version ) (Open Access)
- Published
- 2021
19. Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial.
- Author
-
Demmelmaier, I., Brooke, H.L., Henriksson, A., Mazzoni, A.S., Bjørke, A.C.H., Igelström, H., Ax, A.K., Sjövall, K., Hellbom, M., Pingel, R., Lindman, H., Johansson, S., Velikova, G., Raastad, T., Buffart, L.M., Åsenlöf, P., Aaronson, N.K., Glimelius, B., Nygren, P., Johansson, B., Börjeson, S., Berntsen, S., Nordin, K., Demmelmaier, I., Brooke, H.L., Henriksson, A., Mazzoni, A.S., Bjørke, A.C.H., Igelström, H., Ax, A.K., Sjövall, K., Hellbom, M., Pingel, R., Lindman, H., Johansson, S., Velikova, G., Raastad, T., Buffart, L.M., Åsenlöf, P., Aaronson, N.K., Glimelius, B., Nygren, P., Johansson, B., Börjeson, S., Berntsen, S., and Nordin, K.
- Abstract
Item does not contain fulltext, Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low-to-moderate intensity with BCS (n = 145). The 6-month exercise intervention included supervised resistance training and home-based endurance training. CRF was assessed by Multidimensional Fatigue Inventory (MFI, five subscales score range 4-20), and Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F, score range 0-52). Multiple linear regression for main factorial effects was performed according to intention-to-treat, with post-intervention CRF as primary endpoint. Overall, 577 participants (mean age 58.7 years) were randomized. Participants randomized to high- vs low-to-moderate-intensity exercise had lower physical fatigue (MFI Physical Fatigue subscale; mean difference -1.05 [95% CI: -1.85, -0.25]), but the difference was not clinically important (ie <2). We found no differences in other CRF dimensions and no effect of additional BCS. There were few minor adverse events. For CRF, patients undergoing (neo-)adjuvant treatment for breast, prostate or colorectal cancer can safely exercise at high- or low-to-moderate intensity, according to their own preferences. Additional BCS does not provide extra benefit for CRF in supervised, well-controlled exercise interventions.
- Published
- 2021
20. Long-term morbidity and health after early menopause due to oophorectomy in women at increased risk of ovarian cancer: Protocol for a nationwide cross-sectional study with prospective follow-up (HARMOny Study)
- Author
-
Terra, L. (Lara), Hooning, M.J. (Maartje), Heemskerk-Gerritsen, B.A.M. (Bernadette A.M.), Beurden, M. (Marc) van, Roeters van Lennep, J.E. (Jeanine), Doorn, H.C. (Lena) van, Hullu, J.A. (Joanne) de, Mom, C.H. (Constantijne), van Dorst, E.B.L. (Eleonora B.L.), Mourits, M.J. (Marjan), Slangen, A.H.L. (Arjen), Gaarenstroom, K.N. (Katja), Zillikens, M.C. (Carola), Leiner, I. (Tim), Kolk, L.E. (Lizet) van der, Collée, J.M. (Margriet), Wevers, M.R., Ausems, M.G.E.M. (Margreet), Engelen, K. (Klaartje) van, Berger, L.P.V. (Lieke P.V.), van Asperen, C.J. (Christi J.), Gomez-Garcia, E.B. (Encarna B.), van de Beek, I. (Irma), Rookus, M.A. (Matti), Hauptmann, M. (Michael), Bleiker, E.M.A. (Eveline), Schagen, S.B. (Sanne), Aaronson, N.K. (Neil), Maas, A.H.E.M. (Angela H.E.M.), Leeuwen, F.E. (Flora) van, Terra, L. (Lara), Hooning, M.J. (Maartje), Heemskerk-Gerritsen, B.A.M. (Bernadette A.M.), Beurden, M. (Marc) van, Roeters van Lennep, J.E. (Jeanine), Doorn, H.C. (Lena) van, Hullu, J.A. (Joanne) de, Mom, C.H. (Constantijne), van Dorst, E.B.L. (Eleonora B.L.), Mourits, M.J. (Marjan), Slangen, A.H.L. (Arjen), Gaarenstroom, K.N. (Katja), Zillikens, M.C. (Carola), Leiner, I. (Tim), Kolk, L.E. (Lizet) van der, Collée, J.M. (Margriet), Wevers, M.R., Ausems, M.G.E.M. (Margreet), Engelen, K. (Klaartje) van, Berger, L.P.V. (Lieke P.V.), van Asperen, C.J. (Christi J.), Gomez-Garcia, E.B. (Encarna B.), van de Beek, I. (Irma), Rookus, M.A. (Matti), Hauptmann, M. (Michael), Bleiker, E.M.A. (Eveline), Schagen, S.B. (Sanne), Aaronson, N.K. (Neil), Maas, A.H.E.M. (Angela H.E.M.), and Leeuwen, F.E. (Flora) van
- Abstract
Background: BRCA1/2 mutation carriers are recommended to undergo risk-reducing salpingo-oophorectomy (RRSO) at 35 to 45 years of age. RRSO substantially decreases ovarian cancer risk, but at the cost of immediate menopause. Knowledge about the potential adverse effects of premenopausal RRSO, such as increased risk of cardiovascular disease, osteoporosis, cognitive dysfunction, and reduced health-related quality of life (HRQoL), is limited. Objective: The aim of this study is to assess the long-term health effects of premenopausal RRSO on cardiovascular disease, bone health, cognitive functioning, urological complaints, sexual functioning, and HRQoL in women with high familial risk of breast or ovarian cancer. Methods: We will conduct a multicenter cross-sectional study with prospective follow-up, nested in a nationwide cohort of women at high familial risk of breast or ovarian cancer. A total of 500 women who have undergone RRSO before 45 years of age, with a follow-up period of at least 10 years, will be compared with 250 women (frequency matched on current age) who have not undergone RRSO or who have undergone RRSO at over 55 years of age. Participants will complete an online questionnaire on lifestyle, medical history, cardiovascular risk factors, osteoporosis, cognitive function, urological complaints, and HRQoL. A full cardiovascular assessment and assessment of bone mineral density will be performed. Blood samples will be obtained for marker analysis. Cognitive functioning will be assessed objectively with an online neuropsychological test battery. Results: This study was approved by the institutional review board in July 2018. In February 2019, we included our first participant. As of November 2020, we had enrolled 364 participants in our study. Conclusions: Knowledge from this study will contribute to counseling women with a high familial risk of breast/ovarian cancer about the long-term health effects of premenopausal RRSO. The results can also be used to o
- Published
- 2021
- Full Text
- View/download PDF
21. Measuring change in health-related quality of life
- Author
-
Coomans, M.B., Taphoorn, M.J.B., Aaronson, N.K., Baumert, B.G., Bent, M. van den, Bottomley, A., Brandes, A.A., Chinot, O., Coens, C., Gorlia, T., Herrlinger, U., Keime-Guibert, F., Malmstrom, A., Martinelli, F., Stupp, R., Talacchi, A., Weller, M., Wick, W., Reijneveld, J.C., Dirven, L., EORTC Quality Life Grp, EORTC Brain Tumor Grp, Neurology, CCA - Cancer Treatment and quality of life, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
0301 basic medicine ,medicine.medical_specialty ,BEVACIZUMAB ,Medicine (miscellaneous) ,patient-reported outcome ,VALIDATION ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,Quality of life ,Clinical decision making ,law ,medicine ,AcademicSubjects/MED00300 ,Sjukgymnastik ,Group level ,Physiotherapy ,Change score ,Health related quality of life ,business.industry ,brain tumor ,quality of life ,questionnaire ,Original Articles ,Editor's Choice ,030104 developmental biology ,030220 oncology & carcinogenesis ,Scale (social sciences) ,Physical therapy ,Patient-reported outcome ,AcademicSubjects/MED00310 ,business - Abstract
Background Different analytical methods may lead to different conclusions about the impact of treatment on health-related quality of life (HRQoL). This study aimed to examine 3 different methods to evaluate change in HRQoL and to study whether these methods result in different conclusions. Methods HRQoL data from 15 randomized clinical trials were combined (CODAGLIO project). Change in HRQoL scores, measured with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and BN20 questionnaires, was analyzed in 3 ways: (1) at the group level, comparing mean changes in scale/item scores between treatment arms, (2) at the patient level per scale/item, calculating the percentage of patients that deteriorated, improved, or remained stable per scale/item, and (3) at the individual patient level, combining all scales/items. Results Baseline and first follow-up HRQoL data were available for 3727 patients. At the group scale/item level, only the item “hair loss” showed a significant and clinically relevant change (ie, ≥10 points) over time, whereas change scores on the other scales/items were statistically significant only (all P Conclusions Different analytical methods of changes in HRQoL result in distinct conclusions of treatment effects, all of which may be relevant for informing clinical decision making.
- Published
- 2020
22. Opt-out plus, the patients' choice: preferences of cancer patients concerning information and consent regimen for future research with biological samples archived in the context of treatment
- Author
-
Vermeulen, E., Schmidt, M.K., Aaronson, N.K., Kuenen, M., Van der Valk, P., Sietses, C., van den Tol, P., and van Leeuwen, F.E.
- Subjects
Informed consent (Medical law) -- Research ,Cancer patients -- Surveys ,Biological specimens -- Usage ,Biological specimens -- Research ,Health - Published
- 2009
23. The use of differential item functioning analyses to identify cultural differences in responses to the EORTC QLQ-C30
- Author
-
Scott, N.W., Fayers, P.M., Aaronson, N.K., Bottomley, A., de Graeff, A., Groenvold, M., Koller, M., Petersen, M.A., Sprangers, M.A.G., and on behalf of the EORTC and the Quality of Life Cross-Cultural Meta-Analysis Group
- Published
- 2007
- Full Text
- View/download PDF
24. Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
- Author
-
Veldhuijzen, E., Walraven, I., Mitchell, S.A., Moore, E.Y., McKown, S.M., Lauritzen, M., Kim, K.J., Belderbos, J.S., Aaronson, N.K., Veldhuijzen, E., Walraven, I., Mitchell, S.A., Moore, E.Y., McKown, S.M., Lauritzen, M., Kim, K.J., Belderbos, J.S., and Aaronson, N.K.
- Abstract
Contains fulltext : 229401.pdf (publisher's version ) (Open Access), BACKGROUND: The U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) is a library of items for assessing symptomatic adverse events by patient self-report in oncology trials. The aim of this multi-site study was to generate and linguistically validate a Dutch language version of the U.S. PRO-CTCAE for use in the Netherlands and Dutch-speaking Belgium. METHODS: All 124 items in the PRO-CTCAE item library were translated into Dutch using established translation procedures, including dual forward translations, reconciliation, back-translation, reconciliation of the source with the back-translation, and expert reviews. Harmonization of the translation for use in both the Netherlands and Belgium was achieved via an iterative review process in which the translations were discussed and reconciled by consensus of PRO experts, clinicians and bilingual Dutch translators. The translated PRO-CTCAE™ items were completed by a geographically-diverse sample of Dutch speaking patients from the Netherlands (n = 40) and Belgium (n = 60), and who were currently receiving or who had recently completed cancer-directed therapy. Patients were diverse with respect to age, sex, educational attainment, and cancer diagnosis. Cognitive debriefing, using a semi-structured interview guide, probed for comprehension and clarity of PRO-CTCAE symptom terms, attributes (e.g. frequency, severity, interference), response choices, and understanding of 'at its worst' and 'in the last 7 days'. Items for which the patient data indicated possible difficulties were considered for revision. RESULTS: Three items underwent minor phrasing revision and retesting was not deemed necessary. The symptom term for stretch marks was poorly understood by 12.5% of participants, and this item was revised to include parenthetical phrasing. It was retested with 10 participants from Belgium (n = 5) and the Netherlands (n = 5) and demonstrated acce
- Published
- 2020
25. The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the 'Real-World': Results from the Population-Based PROFILES Registry
- Author
-
Husson, O., Rooij, B.H. de, Kieffer, Jacobien M., Oerlemans, S., Mols, F., Aaronson, N.K., Graaf, W.T.A. van der, Poll-Franse, L.V. van de, Husson, O., Rooij, B.H. de, Kieffer, Jacobien M., Oerlemans, S., Mols, F., Aaronson, N.K., Graaf, W.T.A. van der, and Poll-Franse, L.V. van de
- Abstract
Contains fulltext : 218606.pdf (Publisher’s version ) (Open Access)
- Published
- 2020
26. Adherence to and satisfaction with low-intensity physical activity and supervised moderate-high intensity exercise during chemotherapy for breast cancer.
- Author
-
Waart, H. van, Buffart, L.M., Stuiver, M.M., Harten, W.H. van, Sonke, G.S., Aaronson, N.K., Waart, H. van, Buffart, L.M., Stuiver, M.M., Harten, W.H. van, Sonke, G.S., and Aaronson, N.K.
- Abstract
Item does not contain fulltext, PURPOSE: In this study, we investigated factors associated with program adherence and patient satisfaction with a home-based physical activity program (Onco-Move, N = 77) and a supervised exercise program with a home-based component (OnTrack, N = 76). METHODS: We assessed adherence via self-report (home-based program) and attendance records (supervised program). We used logistic regression analysis to identify sociodemographic, clinical and behavioural variables associated with program adherence. Patient satisfaction was assessed with self-report and is reported descriptively. RESULTS: Fifty-one percent of Onco-Move and 62% of OnTrack participants were adherent to the home-based program, while 59% of OnTrack participants were adherent to the supervised sessions. Higher baseline physical fitness was associated with higher adherence to home-based components. Higher disease stage and having a partner were associated with adherence to OnTrack supervised sessions. Overall satisfaction with the exercise programs was high, but ratings of coaching provided by professionals for the home-based components were low. Patients offered suggestions for improving delivery of the programs. CONCLUSIONS: These findings point to factors relevant to program adherence and suggest ways in which such programs can be improved. Providing additional time and training for health care professionals could improve the quality and hopefully the effectiveness of the interventions. The use of online diaries and smartphone apps may provide additional encouragement to participants. Finally, allowing greater flexibility in the planning and availability of supervised exercise training in order to accommodate the variability in cancer treatment schedules and the (acute) side effects of the treatments could also enhance program adherence. TRIAL REGISTRATION: Netherlands Trial Register, NTR2159. http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2159.
- Published
- 2020
27. Moderators of Exercise Effects on Cancer-related Fatigue: A Meta-analysis of Individual Patient Data.
- Author
-
Vulpen, J.K. van, Sweegers, M.G., Peeters, P.H., Courneya, K.S., Newton, R.U., Aaronson, N.K., Jacobsen, P.B., Galvao, D.A., Chinapaw, M.J., Steindorf, K., Irwin, M.L., Stuiver, M.M., Hayes, S., Griffith, K.A., Mesters, I., Knoop, H., Goedendorp, M.M., Mutrie, N., Daley, A.J., McConnachie, A., Bohus, M., Thorsen, L., Schulz, K.H., Short, C.E., James, E.L., Plotnikoff, R.C., Schmidt, M.E., Ulrich, C.M., Beurden, M. van, Oldenburg, H.S., Sonke, G.S., Harten, W.H. van, Schmitz, K.H., Winters-Stone, K.M., Velthuis, M.J., Taaffe, D.R., Mechelen, W. van, Kersten, M.J., Nollet, F., Wenzel, J., Wiskemann, J., Verdonck-de Leeuw, I.M., Brug, J., May, A.M., Buffart, L.M., Vulpen, J.K. van, Sweegers, M.G., Peeters, P.H., Courneya, K.S., Newton, R.U., Aaronson, N.K., Jacobsen, P.B., Galvao, D.A., Chinapaw, M.J., Steindorf, K., Irwin, M.L., Stuiver, M.M., Hayes, S., Griffith, K.A., Mesters, I., Knoop, H., Goedendorp, M.M., Mutrie, N., Daley, A.J., McConnachie, A., Bohus, M., Thorsen, L., Schulz, K.H., Short, C.E., James, E.L., Plotnikoff, R.C., Schmidt, M.E., Ulrich, C.M., Beurden, M. van, Oldenburg, H.S., Sonke, G.S., Harten, W.H. van, Schmitz, K.H., Winters-Stone, K.M., Velthuis, M.J., Taaffe, D.R., Mechelen, W. van, Kersten, M.J., Nollet, F., Wenzel, J., Wiskemann, J., Verdonck-de Leeuw, I.M., Brug, J., May, A.M., and Buffart, L.M.
- Abstract
01 februari 2020, Contains fulltext : 220990.pdf (Publisher’s version ) (Closed access), PURPOSE: Fatigue is a common and potentially disabling symptom in patients with cancer. It can often be effectively reduced by exercise. Yet, effects of exercise interventions might differ across subgroups. We conducted a meta-analysis using individual patient data of randomized controlled trials (RCT) to investigate moderators of exercise intervention effects on cancer-related fatigue. METHODS: We used individual patient data from 31 exercise RCT worldwide, representing 4366 patients, of whom 3846 had complete fatigue data. We performed a one-step individual patient data meta-analysis, using linear mixed-effect models to analyze the effects of exercise interventions on fatigue (z score) and to identify demographic, clinical, intervention- and exercise-related moderators. Models were adjusted for baseline fatigue and included a random intercept on study level to account for clustering of patients within studies. We identified potential moderators by testing their interaction with group allocation, using a likelihood ratio test. RESULTS: Exercise interventions had statistically significant beneficial effects on fatigue (beta = -0.17; 95% confidence interval [CI], -0.22 to -0.12). There was no evidence of moderation by demographic or clinical characteristics. Supervised exercise interventions had significantly larger effects on fatigue than unsupervised exercise interventions (betadifference = -0.18; 95% CI -0.28 to -0.08). Supervised interventions with a duration =12 wk showed larger effects on fatigue (beta = -0.29; 95% CI, -0.39 to -0.20) than supervised interventions with a longer duration. CONCLUSIONS: In this individual patient data meta-analysis, we found statistically significant beneficial effects of exercise interventions on fatigue, irrespective of demographic and clinical characteristics. These findings support a role for exercise, preferably supervised exercise interventions, in clinical practice. Reasons for differential effects in duration require fur
- Published
- 2020
28. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
- Author
-
Page, E.C., Bancroft, E.K., Aaronson, N.K., and Klinische Psychologie (Psychologie, FMG)
- Subjects
endocrine system diseases ,urologic and male genital diseases ,skin and connective tissue diseases - Abstract
BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at biopsy than PSA alone (AUC = 0.65). CONCLUSIONS: After 3 yr of screening, compared with noncarriers, BRCA2 mutation carriers were associated with a higher incidence of PrCa, younger age of diagnosis, and clinically significant tumours. Therefore, systematic PSA screening is indicated for men with a BRCA2 mutation. Further follow-up is required to assess the role of screening in BRCA1 mutation carriers. PATIENT SUMMARY: We demonstrate that after 3 yr of prostate-specific antigen (PSA) testing, we detect more serious prostate cancers in men with BRCA2 mutations than in those without these mutations. We recommend that male BRCA2 carriers are offered systematic PSA screening.
- Published
- 2019
29. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion
- Author
-
Noorda, E.M., van Kreij, R.H.J., Vrouenraets, B.C., Nieweg, O.E., Muller, M., Kroon, B.B.R., and Aaronson, N.K.
- Published
- 2007
- Full Text
- View/download PDF
30. PCN77 COST-UTILITY, COST-EFFECTIVENESS, AND BUDGET IMPACT OF INTERNET-BASED COGNITIVE BEHAVIOURAL THERAPY FOR BREAST CANCER SURVIVORS WITH TREATMENT-INDUCED MENOPAUSAL SYMPTOMS
- Author
-
Verbeek, J.G.E., primary, Atema, V., additional, Mewes, J.C., additional, van Leeuwen, M., additional, Oldenburg, H.S.A., additional, van Beurden, M., additional, Hunter, M.S., additional, van Harten, W.H., additional, Aaronson, N.K., additional, and Retèl, V.P., additional
- Published
- 2019
- Full Text
- View/download PDF
31. Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma
- Author
-
Osoba, D., Aaronson, N.K., Muller, M., Sneeuw, K., Hsu, M.-A., Yung, W.K.A., Brada, M., and Newlands, E.
- Published
- 1997
- Full Text
- View/download PDF
32. Long-term quality of life among Dutch prostate cancer survivors: results of a population-based study
- Author
-
Mols, Floortje, van de Poll-Franse, L.V., Vingerhoets, A.J.J.M., Hendrikx, A., Aaronson, N.K., Houterman, S., Coebergh, J.W.W., and Essink-Bot, M.L.
- Subjects
Prostate cancer -- Patient outcomes ,Prostate cancer -- Research ,Quality of life -- Research ,Dutch Americans -- Health aspects ,Cancer patients -- Surveys ,Health - Published
- 2006
33. The evaluation of the risks and benefits of phase II cancer clinical trials by institutional review board (IRB) members: a case study
- Author
-
van Luijn, H.E.M., Aaronson, N.K., Keus, R.B., and Musschenga, A.W.
- Subjects
Risk assessment -- Methods ,Health ,Philosophy and religion - Abstract
Objectives: There are indications that institutional review board (IRB) members do not find it easy to assess the risks and benefits in medical experiments, although this is their principal duty. This study examined how IRB members assessed the risk/benefit ratio (RBR) of a specific phase II breast cancer clinical trial. Participants and methods: The trial was evaluated by means of a questionnaire administered to 43 members of IRBs at six academic hospitals and specialised cancer centres in the Netherlands. The questionnaire addressed: identification and estimation of inconvenience, toxicity, psychosocial distress, and benefits of trial participation to patients; identification and estimation of benefits to future patients and medical science; assessment of the trial's RBR; and assessment of its ethical acceptability. Results: Most IRB members expected trial participation to involve fairly or very serious inconvenience, fairly severe to sometimes life-threatening toxicity, and serious psychological and social consequences. Conversely, the perceived likelihood of benefits to patients was modest. Most regarded the study as important, and the balance between risks and benefits to be favourable, and believed that the protocol should be approved. The IRB members' final judgement on the trial's ethical acceptability was significantly correlated with their RBR assessment of the protocol. Conclusions: Because most patients who participate in clinical trials hope this will prolong their lives, it is suggested that patient information should better describe the anticipated benefits-for example, the likelihood of prolonging life. This would allow patients to make decisions regarding participation based on realistic expectations.
- Published
- 2006
34. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.
- Author
-
Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., Schmutzler R.K., Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., and Schmutzler R.K.
- Abstract
Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective(s): To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at
- Published
- 2019
35. Risk factors of unmet needs among women with breast cancer in the post-treatment phase
- Author
-
Lo-Fo-Wong, D. (Deborah), Haes, H.C.J.M. (Hanneke) de, Aaronson, N.K. (Neil), van Abbema, D.L. (Doris L.), den Boer, M.D. (Mathilda D.), Hezewijk, M. (Marjan) van, Immink, M. (Marcelle), Kaptein, A.A. (Ad A.), Menke-Pluijmers, M., Reyners, A.K.L. (Anna), Russell, N.S. (Nicola), Schriek, M. (Manon), Sijtsema, S. (Sieta), Tienhoven, G. (G.) van, Verdam, M.G.E. (Mathilde G. E.), Sprangers, M.A.G. (Mirjam), Lo-Fo-Wong, D. (Deborah), Haes, H.C.J.M. (Hanneke) de, Aaronson, N.K. (Neil), van Abbema, D.L. (Doris L.), den Boer, M.D. (Mathilda D.), Hezewijk, M. (Marjan) van, Immink, M. (Marcelle), Kaptein, A.A. (Ad A.), Menke-Pluijmers, M., Reyners, A.K.L. (Anna), Russell, N.S. (Nicola), Schriek, M. (Manon), Sijtsema, S. (Sieta), Tienhoven, G. (G.) van, Verdam, M.G.E. (Mathilde G. E.), and Sprangers, M.A.G. (Mirjam)
- Abstract
Objective: Unmet health care needs require additional care resources to achieve optimal patient well-being. In this nationwide study we examined associations between a number of risk factors and unmet needs after treatment among women with breast cancer, while taking into account their health care practices. We expected that more care use would be associated with lower levels of unmet needs. Methods: A multicenter, prospective, observational design was employed. Women with primary breast cancer completed questionnaires 6 and 15 months post-diagnosis. Medical data were retrieved from medical records. Direct and indirect associations between sociodemographic and clinical risk factors, distress, care use, and unmet needs were investigated with structural equation modeling. Results: Seven hundred forty-six participants completed both questionnaires (response rate 73.7%). The care services received were not negatively associated with the reported levels of unmet needs after treatment. Comorbidity was associated with higher physical and daily living needs. Higher age was associated with higher health system-related and informational needs. Having had chemotherapy and a mastectomy were associated with higher sexuality needs and breast cancer-specific issues, respectively. A higher level of distress was associated with higher levels of unmet need in all domains. Conclusions: Clinicians may use these results to timely identify which women are at risk of developing specific unmet needs after treatment. Evidence-based, cost-effective (online) interventions that target distress, the most influential risk factor, should be further implemented and disseminated among patients and clinicians.
- Published
- 2019
- Full Text
- View/download PDF
36. Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status?
- Author
-
Coomans, M.B., Dirven, L, Aaronson, N.K. (Neil), Baumert, B.G. (Brigitta), Bent, M.J. (Martin) van den, Bottomley, A. (Andrew), Brandes, A. (Alba), Chinot, O, Coens, C. (Corneel), Gorlia, T.S. (Thierry), Herrlinger, U, Keime-Guibert, F., Malmstrom, A, Martinelli, F, Stupp, R. (Roger), Talacchi, A., Weller, M. (Michael), Wick, W. (Wolfgang), Reijneveld, J.C., Taphoorn, MJ, Coomans, M.B., Dirven, L, Aaronson, N.K. (Neil), Baumert, B.G. (Brigitta), Bent, M.J. (Martin) van den, Bottomley, A. (Andrew), Brandes, A. (Alba), Chinot, O, Coens, C. (Corneel), Gorlia, T.S. (Thierry), Herrlinger, U, Keime-Guibert, F., Malmstrom, A, Martinelli, F, Stupp, R. (Roger), Talacchi, A., Weller, M. (Michael), Wick, W. (Wolfgang), Reijneveld, J.C., and Taphoorn, MJ
- Abstract
Background. Symptom management in glioma patients remains challenging, as patients suffer from various concurrently occurring symptoms. This study aimed to identify symptom clusters and examine the association between these symptom clusters and patients’ functioning. Methods. Data of the CODAGLIO project was used, including individual patient data from previously published international randomized controlled trials (RCTs) in glioma patients. Symptom prevalence and level of functioning were assessed with European Organisation for Research and Treatment of Cancer (EORTC) quality of life QLQC30 and QLQ-BN20 self-report questionnaires. Associations between symptoms were examined with Spearman correlation coefficients and partial correlation networks. Hierarchical cluster analyses were performed to identify symptom clusters. Multivariable regression analyses were performed to determine independent associations between the symptom clusters and functioning, adjusted for possible confounders. Results. Included in the analysis were 4307 newly diagnosed glioma patients from 11 RCTs who completed the EORTC questionnaires before randomization. Many patients (44%) suffered from 5–10 symptoms simultaneously. Four symptom clusters were identified: a motor cluster, a fatigue cluster, a pain cluster, and a gastrointestinal/seizures/bladder control cluster. Having symptoms in the motor cluster was associated with decreased (≥10 points difference) physical, role, and
- Published
- 2019
- Full Text
- View/download PDF
37. Quality of life in breast cancer patients aged over 70 years, participating in the EORTC 10850 randomised clinical trial
- Author
-
de Haes, J.C.J.M, Curran, D, Aaronson, N.K, and Fentiman, I.S
- Published
- 2003
- Full Text
- View/download PDF
38. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire
- Author
-
Petersen, M.A., Aaronson, N.K., Arraras, J.I., Chie, W.C., Conroy, T., Costantini, A., Dirven, L., Fayers, P., Gamper, E.M., Giesinger, J.M., Habets, E.J.J., Hammerlid, E., Helbostad, J., Hjermstad, M.J., Holzner, B., Johnson, C., Kemmler, G., King, M.T., Kaasa, S., Loge, J.H., Reijneveld, J.C., Singer, S., Taphoorn, M.J.B., Thamsborg, L.H., Tomaszewski, K.A., Velikova, G., Verdonck-de Leeuw, I.M., Young, T., Groenvold, M., European Org Res Treatment Cancer, Neurology, Otolaryngology / Head & Neck Surgery, APH - Mental Health, and APH - Personalized Medicine
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Psychometrics ,Health Status ,Item banking ,Item bank ,Taiwan ,Sample (statistics) ,Item response theory ,Statistical power ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,Cost of Illness ,Software Design ,Neoplasms ,Activities of Daily Living ,medicine ,Health Status Indicators ,Humans ,Medical physics ,Health related quality of life ,030212 general & internal medicine ,Patient Reported Outcome Measures ,Patient-reported outcome ,Item development ,Comparability ,EORTC QLQ-C30 ,Middle Aged ,humanities ,3. Good health ,Europe ,Computerized adaptive test ,Oncology ,Sample size determination ,030220 oncology & carcinogenesis ,Quality of Life ,Female ,Psychology - Abstract
Background To optimise measurement precision, relevance to patients and flexibility, patient-reported outcome measures (PROMs) should ideally be adapted to the individual patient/study while retaining direct comparability of scores across patients/studies. This is achievable using item banks and computerised adaptive tests (CATs). The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) is one of the most widely used PROMs in cancer research and clinical practice. Here we provide an overview of the research program to develop CAT versions of the QLQ-C30's 14 functional and symptom domains. Methods The EORTC Quality of Life Group's strategy for developing CAT item banks consists of: literature search to identify potential candidate items; formulation of new items compatible with the QLQ-C30 item style; expert evaluations and patient interviews; field-testing and psychometric analyses, including factor analysis, item response theory calibration and simulation of measurement properties. In addition, software for setting up, running and scoring CAT has been developed. Results Across eight rounds of data collections, 9782 patients were recruited from 12 countries for the field-testing. The four phases of development resulted in a total of 260 unique items across the 14 domains. Each item bank consists of 7–34 items. Psychometric evaluations indicated higher measurement precision and increased statistical power of the CAT measures compared to the QLQ-C30 scales. Using CAT, sample size requirements may be reduced by approximately 20–35% on average without loss of power. Conclusions The EORTC CAT Core represents a more precise, powerful and flexible measurement system than the QLQ-C30. It is currently being validated in a large independent, international sample of cancer patients. © 2018. This is the authors’ accepted and refereed manuscript to the article. Locked until 21..2019 due to copyright restrictions. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
- Published
- 2018
39. Quality of life in the CRITICS study, a multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer
- Author
-
Amelsfoort, R. van, Walraven, I., Jansen, E.P.M., Cats, A., Grieken, N.C.T. van, Aaronson, N.K., Boot, H., Lind, P.A., Kranenbarg, E.M.K., Nordsmark, M., Putter, H., Trip, A.K., Sandick, J.W. van, Sikorska, K., Tinteren, H. van, Velde, C.J.H. van de, and Verheij, M.
- Published
- 2018
40. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States
- Author
-
Nolte, S., primary, Liegl, G., additional, Petersen, M.A., additional, Aaronson, N.K., additional, Costantini, A., additional, Fayers, P.M., additional, Groenvold, M., additional, Holzner, B., additional, Johnson, C.D., additional, Kemmler, G., additional, Tomaszewski, K.A., additional, Waldmann, A., additional, Young, T.E., additional, and Rose, M., additional
- Published
- 2019
- Full Text
- View/download PDF
41. Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core
- Author
-
Liegl, G., primary, Petersen, M.A., additional, Groenvold, M., additional, Aaronson, N.K., additional, Costantini, A., additional, Fayers, P.M., additional, Holzner, B., additional, Johnson, C.D., additional, Kemmler, G., additional, Tomaszewski, K.A., additional, Waldmann, A., additional, Young, T.E., additional, Rose, M., additional, and Nolte, S., additional
- Published
- 2019
- Full Text
- View/download PDF
42. Australian utility weights for the EORTC QLU-C10D, a multi-attribute utility instrument derived from the cancer-specific quality of life questionnaire, EORTC QLQ-C30
- Author
-
King, M.T., Viney, R., Pickard, A.S., Rowen, D.L., Aaronson, N.K., Brazier, J.E., Cella, D.F., Costa, D.S.J., Fayers, P.M., Kemmler, G., McTaggart-Cowan, H., Mercieca-Bebber, R., Peacock, S., Street, D., Young, T.A., and Norman, R.
- Abstract
Background: The EORTC QLU-C10D is a new multi-attribute utility instrument derived from the widely-used cancer-specific quality of life questionnaire, EORTC QLQ-C30. The QLU-C10D contains ten dimensions (Physical, Role, Social and Emotional Functioning; Pain, Fatigue, Sleep, Appetite, Nausea, Bowel Problems), each with 4 levels. To be used in cost-utility analysis, country-specific valuation sets are required.\ud Objective: To provide Australian utility weights for the QLU-C10D.\ud Methods: An Australian online panel was quota sampled to ensure population representativeness by sex and age (≥18y). Participants completed a discrete choice experiment (DCE) consisting of 16 choice-pairs. Each pair comprised two QLU-C10D health states plus life expectancy. Data were analysed using conditional logistic regression, parameterised to fit the quality-adjusted life-year framework. Utility weights were calculated as the ratio of each QOL dimension-level coefficient to the coefficient on life expectancy.\ud Results: 1979 panel members opted-in, 1904 (96%) completed at least one choice-pair, and 1846 (93%) completed all 16 choice-pairs. Dimension weights were generally monotonic: poorer levels within each dimension were generally associated with greater utility decrements. The dimensions that impacted most on choice were, in order, Physical Functioning, Pain, Role Functioning and Emotional Functioning. Oncology-relevant dimensions with moderate impact were Nausea and Bowel Problems. Fatigue, Trouble Sleeping and Appetite had relatively small impact. The value of the worst health state was -0.096, somewhat worse than death. \ud Conclusions: This study provides the first country-specific value set for the QLU-C10D, which can facilitate cost-utility analyses when applied to data collected with the EORTC QLQ-C30, prospectively and retrospectively. \ud
- Published
- 2017
43. Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members
- Author
-
van Luijn, H.E.M., Musschenga, A.W., Keus, R.B., Robinson, W.M., and Aaronson, N.K.
- Published
- 2002
- Full Text
- View/download PDF
44. Assessing Quality of Life After Stroke: The Value and Limitations of Proxy Ratings
- Author
-
Sneeuw, K.C.A., Aaronson, N.K., de Haan, R.J., and Limburg, M.
- Published
- 1997
45. Quality of Life After Stroke: Impact of Stroke Type and Lesion Location
- Author
-
de Haan, R.J., Limburg, M., Van der Meulen, J.H.P., Jacobs, H.M., and Aaronson, N.K.
- Published
- 1995
46. Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire
- Author
-
Leeuwen, M. van, Husson, O., Alberti, P., Arraras, J.I., Chinot, O.L., Costantini, A., Darlington, A.S., Dirven, L., Eichler, M., Hammerlid, E.B., Holzner, B., Johnson, C.D., Kontogianni, M., Kjaer, T.K., Morag, O., Nolte, S., Nordin, A., Pace, A., Pinto, M., Polz, K., Ramage, J., Reijneveld, J.C., Serpentini, S., Tomaszewski, K.A., Vassiliou, V., Leeuw, I.M. Verdonck-de, Vistad, I., Young, T.E., Aaronson, N.K., Poll-Franse, L.V. van de, Leeuwen, M. van, Husson, O., Alberti, P., Arraras, J.I., Chinot, O.L., Costantini, A., Darlington, A.S., Dirven, L., Eichler, M., Hammerlid, E.B., Holzner, B., Johnson, C.D., Kontogianni, M., Kjaer, T.K., Morag, O., Nolte, S., Nordin, A., Pace, A., Pinto, M., Polz, K., Ramage, J., Reijneveld, J.C., Serpentini, S., Tomaszewski, K.A., Vassiliou, V., Leeuw, I.M. Verdonck-de, Vistad, I., Young, T.E., Aaronson, N.K., and Poll-Franse, L.V. van de
- Abstract
Contains fulltext : 193494.pdf (publisher's version ) (Open Access), BACKROUND: The number of cancer survivors is growing steadily and increasingly, clinical trials are being designed to include long-term follow-up to assess not only survival, but also late effects and health-related quality of life (HRQOL). Therefore it is is essential to develop patient-reported outcome measures (PROMs) that capture the full range of issues relevant to disease-free cancer survivors. The objectives of this project are: 1) to develop a European Organisation for Research and Treatment of Cancer (EORTC) questionnaire that captures the full range of physical, mental and social HRQOL issues relevant to disease-free cancer survivors; and 2) to determine at which minimal time since completion of treatment the questionnaire should be used. METHODS: We reviewed 134 publications on cancer survivorship and interviewed 117 disease-free cancer survivors with 11 different types of cancer across 14 countries in Europe to generate an exhaustive, provisional list of HRQOL issues relevant to cancer survivors. The resulting issue list, the EORTC core questionnaire (QLQ-C30), and site-specific questionnaire modules were completed by a second group of 458 survivors. RESULTS: We identified 116 generic survivorship issues. These issues covered body image, cognitive functioning, health behaviors, negative and positive outlook, health distress, mental health, fatigue, sleep problems, physical functioning, pain, several physical symptoms, social functioning, and sexual problems. Patients rated most of the acute symptoms of cancer and its treatment (e.g. nausea) as no longer relevant approximately one year after completion of treatment. CONCLUSIONS: Compared to existing cancer survivorship questionnaires, our findings underscore the relevance of assessing issues related to chronic physical side effects of treatment such as neuropathy and joint pain. We will further develop a core survivorship questionnaire and three site-specific modules for disease-free adult cancer survivor
- Published
- 2018
47. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- Author
-
Driel, W.J. van, Koole, S.N., Sikorska, K., Schagen van Leeuwen, J.H., Hermans, R.H., Massuger, L.F.A.G., Aaronson, N.K., Sonke, G.S., Driel, W.J. van, Koole, S.N., Sikorska, K., Schagen van Leeuwen, J.H., Hermans, R.H., Massuger, L.F.A.G., Aaronson, N.K., and Sonke, G.S.
- Abstract
Contains fulltext : 183880.pdf (publisher's version ) (Open Access)
- Published
- 2018
48. Effects and moderators of psychosocial interventions on quality of life, and emotional and social function in patients with cancer: An individual patient data meta-analysis of 22 RCTs
- Author
-
Kalter, J., Verdonck-de Leeuw, I.M., Sweegers, M.G., Aaronson, N.K., Jacobsen, P.B., Newton, R.U., Courneya, K.S., Aitken, J.F., Armes, J., Arving, C., Boersma, L.J., Braamse, A.M.J., Brandberg, Y., Chambers, S.K., Dekker, J., Ell, K., Ferguson, R.J., Gielissen, M.F.M., Glimelius, B., Goedendorp, M.M., Graves, K.D., Heiney, S.P., Horne, R., Hunter, M.S., Johansson, B., Kimman, M.L., Knoop, H., Meneses, K., Northouse, L.L., Oldenburg, H.S., Prins, J.B., Savard, J., Beurden, M. van, Berg, S.W. van den, Brug, J., Buffart, L.M., Kalter, J., Verdonck-de Leeuw, I.M., Sweegers, M.G., Aaronson, N.K., Jacobsen, P.B., Newton, R.U., Courneya, K.S., Aitken, J.F., Armes, J., Arving, C., Boersma, L.J., Braamse, A.M.J., Brandberg, Y., Chambers, S.K., Dekker, J., Ell, K., Ferguson, R.J., Gielissen, M.F.M., Glimelius, B., Goedendorp, M.M., Graves, K.D., Heiney, S.P., Horne, R., Hunter, M.S., Johansson, B., Kimman, M.L., Knoop, H., Meneses, K., Northouse, L.L., Oldenburg, H.S., Prins, J.B., Savard, J., Beurden, M. van, Berg, S.W. van den, Brug, J., and Buffart, L.M.
- Abstract
Item does not contain fulltext, OBJECTIVE: This individual patient data (IPD) meta-analysis aimed to evaluate the effects of psychosocial interventions (PSI) on quality of life (QoL), emotional function (EF), and social function (SF) in patients with cancer, and to study moderator effects of demographic, clinical, personal, and intervention-related characteristics. METHODS: Relevant studies were identified via literature searches in 4 databases. We pooled IPD from 22 (n = 4217) of 61 eligible randomized controlled trials. Linear mixed-effect model analyses were used to study intervention effects on the post-intervention values of QoL, EF, and SF (z-scores), adjusting for baseline values, age, and cancer type. We studied moderator effects by testing interactions with the intervention for demographic, clinical, personal, and intervention-related characteristics, and conducted subsequent stratified analyses for significant moderator variables. RESULTS: PSI significantly improved QoL (beta = 0.14,95%CI = 0.06;0.21), EF (beta = 0.13,95%CI = 0.05;0.20), and SF (beta = 0.10,95%CI = 0.03;0.18). Significant differences in effects of different types of PSI were found, with largest effects of psychotherapy. The effects of coping skills training were moderated by age, treatment type, and targeted interventions. Effects of psychotherapy on EF may be moderated by cancer type, but these analyses were based on 2 randomized controlled trials with small sample sizes of some cancer types. CONCLUSIONS: PSI significantly improved QoL, EF, and SF, with small overall effects. However, the effects differed by several demographic, clinical, personal, and intervention-related characteristics. Our study highlights the beneficial effects of coping skills training in patients treated with chemotherapy, the importance of targeted interventions, and the need of developing interventions tailored to the specific needs of elderly patients.
- Published
- 2018
49. Targeting Exercise Interventions to Patients With Cancer in Need: An Individual Patient Data Meta-Analysis
- Author
-
Buffart, L.M., Sweegers, M.G., May, A.M., Chinapaw, M.J., Vulpen, J.K. van, Newton, R.U., Galvao, D.A., Aaronson, N.K., Stuiver, M.M., Jacobsen, P.B., Verdonck-de Leeuw, I.M., Steindorf, K., Irwin, M.L., Hayes, S., Griffith, K.A., Lucia, A., Herrero-Roman, F., Mesters, I., Weert, E. Van, Knoop, H., Goedendorp, M.M., Mutrie, N., Daley, A.J., McConnachie, A., Bohus, M., Thorsen, L., Schulz, K.H., Short, C.E., James, E.L., Plotnikoff, R.C., Arbane, G., Schmidt, M.E., Potthoff, K., Beurden, M. van, Oldenburg, H.S., Sonke, G.S., Harten, W.H. van, Garrod, R., Schmitz, K.H., Winters-Stone, K.M., Velthuis, M.J., Taaffe, D.R., Mechelen, W. van, Kersten, M., Nollet, F., Wenzel, J., Wiskemann, J., Brug, J., Courneya, K.S., Buffart, L.M., Sweegers, M.G., May, A.M., Chinapaw, M.J., Vulpen, J.K. van, Newton, R.U., Galvao, D.A., Aaronson, N.K., Stuiver, M.M., Jacobsen, P.B., Verdonck-de Leeuw, I.M., Steindorf, K., Irwin, M.L., Hayes, S., Griffith, K.A., Lucia, A., Herrero-Roman, F., Mesters, I., Weert, E. Van, Knoop, H., Goedendorp, M.M., Mutrie, N., Daley, A.J., McConnachie, A., Bohus, M., Thorsen, L., Schulz, K.H., Short, C.E., James, E.L., Plotnikoff, R.C., Arbane, G., Schmidt, M.E., Potthoff, K., Beurden, M. van, Oldenburg, H.S., Sonke, G.S., Harten, W.H. van, Garrod, R., Schmitz, K.H., Winters-Stone, K.M., Velthuis, M.J., Taaffe, D.R., Mechelen, W. van, Kersten, M., Nollet, F., Wenzel, J., Wiskemann, J., Brug, J., and Courneya, K.S.
- Abstract
Item does not contain fulltext, Background: Exercise effects in cancer patients often appear modest, possibly because interventions rarely target patients most in need. This study investigated the moderator effects of baseline values on the exercise outcomes of fatigue, aerobic fitness, muscle strength, quality of life (QoL), and self-reported physical function (PF) in cancer patients during and post-treatment. Methods: Individual patient data from 34 randomized exercise trials (n = 4519) were pooled. Linear mixed-effect models were used to study moderator effects of baseline values on exercise intervention outcomes and to determine whether these moderator effects differed by intervention timing (during vs post-treatment). All statistical tests were two-sided. Results: Moderator effects of baseline fatigue and PF were consistent across intervention timing, with greater effects in patients with worse fatigue (Pinteraction = .05) and worse PF (Pinteraction = .003). Moderator effects of baseline aerobic fitness, muscle strength, and QoL differed by intervention timing. During treatment, effects on aerobic fitness were greater for patients with better baseline aerobic fitness (Pinteraction = .002). Post-treatment, effects on upper (Pinteraction < .001) and lower (Pinteraction = .01) body muscle strength and QoL (Pinteraction < .001) were greater in patients with worse baseline values. Conclusion: Although exercise should be encouraged for most cancer patients during and post-treatments, targeting specific subgroups may be especially beneficial and cost effective. For fatigue and PF, interventions during and post-treatment should target patients with high fatigue and low PF. During treatment, patients experience benefit for muscle strength and QoL regardless of baseline values; however, only patients with low baseline values benefit post-treatment. For aerobic fitness, patients with low baseline values do not appear to benefit from exercise during treatment.
- Published
- 2018
50. Shared decision-making in prostate cancer care
- Author
-
Bosch, JLHR, Aaronson, N.K., van der Poel, Henk, van Stam, M.A., Bosch, JLHR, Aaronson, N.K., van der Poel, Henk, and van Stam, M.A.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.